{"doi":"10.1007/s11523-021-00840-3","title":"The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges","abstract":null,"journal":"Targeted Oncology","year":2021,"id":633614,"datarank":0.5456379239589579,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":0.0,"self_endowment_contribution":0.5456379239589579,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":95241,"name":"Maximilian Haist","orcid":"0000-0002-6720-7570","position":1,"is_corresponding":false},{"id":1642907,"name":"Ulrike Nikfarjam","orcid":null,"position":2,"is_corresponding":false},{"id":1642911,"name":"Michael Schultheis","orcid":null,"position":3,"is_corresponding":false},{"id":1642915,"name":"Jaqueline Heinz","orcid":null,"position":4,"is_corresponding":false},{"id":1642918,"name":"Saskia Pemler","orcid":null,"position":5,"is_corresponding":false},{"id":28950,"name":"Carmen Loquai","orcid":null,"position":6,"is_corresponding":false},{"id":28951,"name":"Stephan Grabbe","orcid":"0000-0002-6863-8719","position":7,"is_corresponding":false},{"id":1642901,"name":"Henner Stege","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges","abstract":"The global incidence of malignant melanoma, the leading cause of skin cancer death, has steadily increased in recent years. Surgical excision is the treatment of choice for early-stage melanoma. However, 40-60% of patients with high-risk melanoma or with nodal involvement eventually experience loco-regional relapse or tumor progression. Adjuvant therapy aims to reduce the rate of recurrence in radically operated high-risk patients with melanoma and thus improves survival. Interferon-α has long been the only approved drug for adjuvant melanoma therapy, despite an unclear survival benefit. The landmark success of immune-checkpoint inhibitors and BRAF/MEK-directed targeted therapies in the treatment of patients with stage IV melanoma led to the initiation of clinical trials in the adjuvant setting. These trials demonstrated the efficacy of immune-checkpoint inhibitors and targeted therapies for the adjuvant treatment of high-risk patients with melanoma, as shown both by an increase in recurrence-free survival and the emergence of long-term survivors, finally resulting in the approval of the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab, PD1 inhibitors (nivolumab, pembrolizumab), and BRAF/MEK inhibitors for adjuvant melanoma therapy. This review aims to delineate the advances in adjuvant melanoma therapy, issuing particularly recent results from clinical trials. Moreover, we also discuss pending issues and future challenges, which comprise the adequate selection of adjuvant regimens for patient subgroups and the identification of markers likely to predict the individual response to adjuvant treatments. Last, we outline the role of emerging neoadjuvant approaches, which may complement adjuvant strategies and are currently investigated in clinical trials.","is_dataset_classified":null,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34554353","pmcid":"PMC8484171","openalex_id":"https://openalex.org/W3200550458","authors":[],"funders":[{"funder_name":"else kröner-fresenius-stiftung","grant_id":"TransMed Jumpstart Program: 2019_A72","title":null},{"funder_name":"german research council","grant_id":"SFB TR156","title":null},{"funder_name":"german research council","grant_id":"B11","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft","grant_id":"213555243/SFB 1066","title":"Nano-Dimensional Polymer Therapeutics for Tumor Therapy"},{"funder_name":"Universitätsmedizin der Johannes Gutenberg-Universität Mainz","grant_id":"","title":null},{"funder_name":"Open Access funding enabled and organized by Projekt DEAL.","grant_id":"","title":null}],"total_grants":6,"fwci":2.5942,"citation_percentile":0.92842919,"influential_citations":0,"citation_trend":[{"year":2022,"count":10},{"year":2023,"count":17},{"year":2024,"count":5},{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00840-3.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00840-3.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s11523-021-00840-3/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s11523-021-00840-3","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34554353","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC8484171","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8484171","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8484171","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8484171?pdf=render","host_type":"Europe_PMC"},{"url":"https://dx.doi.org/10.25358/openscience-7641","host_type":""},{"url":"http://dx.doi.org/10.1007/s11523-021-00840-3","host_type":""},{"url":"https://dx.doi.org/10.1007/s11523-021-00840-3","host_type":""},{"url":"https://doi.org/10.25358/openscience-7641","host_type":""},{"url":"https://openscience.ub.uni-mainz.de/handle/20.500.12030/7655","host_type":""},{"url":"https://doi.org/https://doi.org/20.500.12030/7655","host_type":""},{"url":"https://doi.org/https://doi.org/10.25358/openscience-7641","host_type":""}],"fields_of_study":["Cutaneous Melanoma Detection and Management","Melanoma and MAPK Pathways","Immunotherapy and Immune Responses","0301 basic medicine","03 medical and health sciences","0302 clinical medicine","Humans","Ipilimumab","Melanoma","Neoadjuvant Therapy","Nivolumab","Skin Neoplasms"],"mesh_terms":["Ipilimumab","Nivolumab","Humans","Melanoma","Skin Neoplasms","Neoadjuvant Therapy"],"keywords":["Medicine","Adjuvant","Neoadjuvant therapy","Adjuvant therapy","Melanoma","Oncology","Medical physics","Internal medicine","Cancer","Cancer research","ddc:610","Skin Neoplasms","610 Medizin","610","Review Article","Ipilimumab","Nivolumab","610 Medical sciences","Humans"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:23:05.770312Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}